A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda
While the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of...
Source: Parasites and Vectors - Category: Microbiology Authors: Freddie Kansiime, Seraphine Adibaku, Charles Wamboga, Franklin Idi, Charles Drago Kato, Lawrence Yamuah, Michel Vaillant, Deborah Kioy, Piero Olliaro and Enock Matovu Tags: Research Source Type: research
More News: African Health | African Sleeping Sickness | Clinical Trials | Legislation | Microbiology | Parasitic Diseases | Parasitology | Sleeping Sickness | Uganda Health